Galapagos N.V.
NASDAQ: GLPG0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Henry O. Gosebruch
- Employees
- 452
- Headquarters
- Mechelen, Belgium
- IPO year
- 2012
- Market cap
- $1.8B
- Website
- https://www.glpg.com
Loading GLPG…
Loading profile data…Frequently asked questions about GLPG
What does Galapagos N.V. (GLPG) do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headq...
Where does GLPG trade?
Galapagos N.V. (GLPG) trades on the NASDAQ.
What sector is GLPG in?
Galapagos N.V. (GLPG) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Galapagos N.V.?
Henry O. Gosebruch is the chief executive officer of Galapagos N.V. (GLPG).
Where is Galapagos N.V. headquartered?
Galapagos N.V. is headquartered in Belgium.
Does GLPG pay a dividend?
Galapagos N.V. (GLPG) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLPG go public?
Galapagos N.V. (GLPG) completed its initial public offering in 2012.